News

Public · Published

MRNA: Revenue and profit rebounded as respiratory sales and Phase III melanoma results advanced

Moderna's third-quarter revenue rose 29% year over year to $1.3B, and net income was $162M. The company raised its FY2026 revenue growth guidance and lowered targets for cash costs and capital spending. It also reported positive Phase III melanoma results for intismeran and expanded respiratory approvals.

Published:

Updated:

What happened

Moderna’s third-quarter revenue rose 29% year over year to $1.3B, and net income was $162M. The company raised its FY2026 revenue growth guidance and lowered targets for cash costs and capital spending. It also reported positive Phase III melanoma results for intismeran and expanded respiratory approvals.

Confirmed

Global impact / market context

Higher respiratory sales and expanded approvals can support revenue, while positive late-stage melanoma results may create another source of future sales if development and approvals progress. Lower cash-cost and capital-spending targets could preserve more cash, but the summary gives no figures or timing for these changes.

Analyst inference

The update combines reported quarterly results with changes to full-year guidance and clinical progress. Revenue growth and net income describe recent performance, while FY2026 guidance and Phase III results relate to future prospects; neither alone establishes how durable growth will be or what commercial contribution melanoma could bring.

Analyst inference

What to watch

  1. Check subsequent results for whether respiratory sales continue to support revenue growth and whether the raised FY2026 guidance remains consistent with reported performance. Analyst inference
  2. Look for details on the lowered cash-cost and capital-spending targets, including their amounts and timing, to assess the expected effect on cash available. Analyst inference
  3. Watch for further updates on intismeran’s melanoma development and respiratory approvals, since these could determine whether clinical progress translates into broader sales. Analyst inference

Evidence

  • Original source link unavailable